Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 21,33 € (+19,16%). Mediana wynosi 21,38 € (+19,44%).
| Kupuj |
7 |
| Trzymaj |
5 |
| Sprzedaj |
1 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Fortrea cooperates with Omico to accelerate biomarker-driven cancer trials in Australia
Fortrea has announced a collaboration with Omico to advance precision oncology research by accelerating the identification and matching of suitable patients to biomarker-driven clinical trials. The partnership combines Fortrea’s expertise in running oncology studies with Omico’s PrOSPeCT platform, molecular profiling data and a network of investigators and trial sites in Australia. The aim is to optimize study design, enable more targeted site selection and speed patient recruitment using genomic data from more than 23,000 patients. » Więcej na finanzen.net
Fortrea completes acquisition of Worldwide Clinical Trials' early phase services business
Fortrea has closed the purchase of Worldwide Clinical Trials' early phase services division for about $45 million. The deal includes a 200-bed CRU in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin and a sample storage facility in Pflugerville. The acquisition brings Fortrea's global early-phase capacity to more than 570 beds and strengthens internal bioanalytical capabilities to better integrate clinical and analytical processes. It is intended to shorten turnaround times, reduce operational handoffs and expand the platform for clinical development. » Więcej na finanzen.net
Fortrea buys early-phase unit from Worldwide for $45 million
Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » Więcej na de.investing.com
Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials
Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » Więcej na finanzen.net
Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials
Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 610,49 mln | 2,16% |
| Zysk brutto | 123,16 mln | 40,18% |
| Zysk netto | 529,71 tys. | 103,91% |
| EBITDA | 32,31 mln | 180,88% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 1,69 mld € |
Liczba akcji | 94,6 mln |
Maksimum/minimum z 52 tygodni | 23,80 € - 7,78 € |
| Dywidendy | Nie |
Beta | 1,86 |
C/Z (PE Ratio) | -25,99 |
PEG (PEG Ratio) | -0,11 |
C/WK (PB Ratio) | 3,52 |
C/S (PS Ratio) | 0,69 |
Profil spółki
Fortrea Holdings Inc. świadczy usługi w zakresie rozwoju klinicznego i dostępu pacjentów do rozwiązań dla branży nauk o życiu. Oferuje zarządzanie badaniami klinicznymi faz I–IV, farmakologię kliniczną, zróżnicowane rozwiązania do prowadzenia badań oparte na technologii oraz usługi posprzedażowe po uzyskaniu zatwierdzenia. Firma obsługuje organizacje farmaceutyczne, biotechnologiczne i producentów wyrobów medycznych. Fortrea Holdings Inc. ma siedzibę w Durham w Karolinie Północnej.
| Nazwa | FORTREA HOLDINGS DL-,001 Aktie |
| CEO | Anshul Thakral |
| Siedziba | Durham,
nc Stany Zjednoczone |
| Strona internetowa | |
| Branża | Ochrona zdrowia: sprzęt i produkty |
| Debiut giełdowy | 20.06.2023 |
| Pracownicy | 14 000 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | FTRE |
Frankfurt | K67.F |
Düsseldorf | K67.DU |
München | K67.MU |